AKT1 and glioblastoma: Preclinical studies have shown that GBM cells exposed to niclosamide simultaneously downregulate multiple cancer cell signalling pathways, including NOTCH, mTOR, MAPK/ERK, and Akt-dependent signalling, leading to reduced cancer cell proliferation, viability, and migration [180,182].